REG3A overexpression functions as a negative predictive and prognostic biomarker in rectal cancer patients receiving CCRT

• Wan-Shan Li ^[1] ; Tzu-Ju Chen ^[1] ; Sung-Wei Lee ^[1] ; Ching-Chieh Yang ^[1] ; Yu-Feng Tian ^[1] ; Yu-Hsuan Kuo ^[1] ; Hsin-Hwa Tsai ^[1] ; Li-Ching Wu ^[1] ; Cheng-Fa Yeh ^[1] ; Yow-Ling Shiue ^[1] ; Chia-Lin Chou ^[1] ; Hong-Yue Lai ^[1]
  1. [1] Chung Hwa University of Medical Technology

     Chung Hwa University of Medical Technology

     Taiwán

     
• Localización: Histology and histopathology: cellular and molecular biology, ISSN-e 1699-5848, ISSN 0213-3911, Vol. 39, Nº. 1, 2024, págs. 91-104
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • y. Background. Concurrent chemoradiotherapy (CCRT) is suggested before resection surgery in the control of rectal cancer. Unfortunately, treatment outcomes are widely variable and highly patientspecific. Notably, rectal cancer patients with distant metastasis generally have a much lower survival rate.

    Accordingly, a better understanding of the genetic background of patient cohorts can aid in predicting CCRT efficacy and clinical outcomes for rectal cancer before distant metastasis.

    Methods. A published transcriptome dataset (GSE35452) (n=46) was utilized to distinguish prospective genes concerning the response to CCRT. We recruited 172 rectal cancer patients, and the samples were collected during surgical resection after CCRT.

    Immunohistochemical (IHC) staining was performed to evaluate the expression level of regenerating family member 3 alpha (REG3A). Pearson's chi-squared test appraised the relevance of REG3A protein expression to clinicopathological parameters. The Kaplan-Meier method was utilized to generate survival curves, and the log-rank test was performed to compare the survival distributions between two given groups.

    Results. Employing a transcriptome dataset (GSE35452) and focusing on the inflammatory response (GO: 0006954), we recognized that REG3A is the most significantly upregulated gene among CCRT nonresponders (log2 ratio=1.2472, p=0.0079). Following IHC validation, high immunoexpression of REG3A wasconsiderably linked to advanced post-CCRT tumor status (p<0.001), post-CCRT lymph node metastasis (p=0.042), vascular invasion (p=0.028), and low-grade tumor regression (p=0.009). In the multivariate analysis, high immunoexpression of REG3A was independently correlated with poor disease-specific survival (DSS) (p=0.004) and metastasis-free survival (MeFS) (p=0.045). The results of the bioinformatic analysis also supported the idea that REG3A overexpression is implicated in rectal carcinogenesis.

    Conclusion. In the current study, we demonstrated that REG3A overexpression is correlated with poor CCRT effectiveness and inferior patient survival in rectal cancer. The predictive and prognostic utility of REG3A expression may direct patient stratification and decisionmaking more accurately for those patients.